Palovarotene for the potential treatment of MHE
Clementia, an Ipsen subsidiary, is actively recruiting patients for an efficacy and safety study of palovarotene, an investigational study drug, for the treatment of multiple osteochondromas (MO-Ped). This is a randomized, double-blind, placebo-controlled study comparing the safety and efficacy of two dosage regimens of palovarotene versus placebo in preventing disease progression in pediatric subjects with MO.
Please visit https://clinicaltrials.gov/ct2/show/NCT03442985 for the current information on clinical study sites and eligibility criteria.
Additional information including “Frequently Asked Questions” is available at www.mopedtrial.com.
Please note that the use of palovarotene in multiple osteochondromas (MO) is not approved by FDA and safety and efficacy have not been established.”
To download a FAQ's document about the trial Click Here.
Clementia has developed a study website. To learn more and see if you or a loved one could potentially qualify, click HERE. A video about the trial details can be found below.
Watch an Informational Video Sponsored By Clementia
The MHE Research Foundation would like to thank and acknowledge Clementia Pharmaceuticals, Maurizio Pacifici, PhD, Yu Yamaguchi, MD, PhD, David Feldman, MD, Dror Paley, MD, FRSCS, Scott Kozin, MD, The Children's Hospital of Philadelphia, Sanford Burnham Prebys Medical Discovery Institute, The Paley Orthopedic & Spine Institute at St. Mary’s Medical Center, The Shriners Hospitals for Children, National Institutes of Health (NIH) and the entire Scientific and Medical Advisory Board of our Foundation as well as many others for their years of dedication and leadership around the world.
Sarah Ziegler, Susan Eaton, Craig Eaton, Esq. and the entire Board of Directors